STOPCAP
Maximising patient benefit through enhanced evaluation of therapies and better characterisation of metastatic hormone-sensitive prostate cancer
STOPCAP is a worldwide collaborative effort that aims to find out which treatments for metastatic hormone-sensitive prostate cancer (mHSPC) are the most effective, and for which men. This will be done through:
Systematic reviews of treatment effects
Reviewing trial results and data in new and different ways to find out quickly which current treatments work best for which men and fast-track the best treatments to men who need them
Identification of surrogate outcomes
Work out if early measures of prostate cancer control (e.g. disease progression) can be used instead of survival when comparing between treatments, so that future clinical trials will take less time to test new treatments than before. Also, work out which characteristics of men and their tumours are best for predicting how long they will live, so that they can be used in the clinic and in future trials.
Improving the uptake of beneficial treatments
Find new and different ways of making sure that findings from clinical research get recommended, and used, in standard practice; so that more patients can benefit more quickly.
Improving the use of existing data
Look at all the different types of data that are collected on men with mHSPC, and see if they can be brought together to better understand the disease and how individuals might respond to treatment.